Bogle Grant C. reported grant involving 66,700 derivative units of Immuneering Corp at $0.00 for $0 on Nov 9, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Nov 9, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
66,700Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
66,700Direct
Trade date
Nov 9, 2026Grant
Filed
Nov 9, 2026, 4:31 PM ET0-day reporting delay
Accession
0001790340-26-000103Code A · Transaction 396024
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

IMRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IMRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on December 9, 2026, and will be fully vested and exercisable on November 9, 2029.